COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,233 Articles (22,733 medRxiv, 8,500 bioRxiv)

Most recent first Previous |  Page 1109: Articles 11081-11090  | Next

Dual Effects of NV-CoV-2 Biomimetic Polymer: An Antiviral regimen against COVID-19
Chakraborty, A., Diwan, A., Chiniga, V., Arora, V., Holkar, P., Thakur, Y., Tatake, J., Barton, R., Holkar, N., Pond, B.
10.1101/2021.11.24.469813 — Posted: 2021-11-26
Synergetic measures needed to control infection waves and contain SARS-CoV-2 transmission
Su, H., Cheng, Y., Poeschl, U.
10.1101/2021.11.24.21266824 — Posted: 2021-11-25
Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons
Tzou, P. L., Tao, K., Pond, S. L. K., Shafer, R. W.
10.1101/2021.11.24.469823 — Posted: 2021-11-24
SARS-CoV-2 variants of concern Alpha, Beta, Gamma and Delta have extended ACE2 receptor host-ranges
Thakur, N., Gallo, G., Newman, J., Peacock, T. P., Biasetti, L., Hall, C. N., Wright, E., Barclay, W., Bailey, D.
10.1101/2021.11.23.469663 — Posted: 2021-11-24
A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity
Adam, A., Shi, Q., Wang, B., Zou, J., Mai, J., Osman, S. R., Wu, W., Xie, X., Aguilar, P. V., Bao, X., Shi, P.-Y., Shen, H., Wang, T.
10.1101/2021.11.22.469576 — Posted: 2021-11-24
Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents
Messiah, S. E., Brito, F. A., Kohl, H. W., DeSantis, S. M., Valerio-Shewmaker, M. A., Ross, J. A., Yaseen, A., Kelder, S. H., Zhang, S., Omega-Njemnobi, O. S., Gonzalez, M. O., Wu, L., Boerwinkle, E. A., Lakey, D., Shuford, J. A., Pont, S.
10.1101/2021.11.21.21266484 — Posted: 2021-11-24
Recurring Spatiotemporal Patterns of COVID-19 in the United States
Jalal, H., Lee, K., Burke, D. S.
10.1101/2021.11.23.21266775 — Posted: 2021-11-24
Reinfection with SARS-CoV-2: outcome, risk factors and vaccine efficacy in a Scottish cohort
McKeigue, P. M., McAllister, D., Robertson, C., Stockton, D., Colhoun, H.
10.1101/2021.11.23.21266574 — Posted: 2021-11-24 Discussion: Onsite
Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals
Andeweg, S. P., Vennema, H., Veldhuijzen, I., Smorenburg, N., Schmitz, D., Zwagemaker, F., SeqNeth Molecular surveillance group, , RIVM COVID-19 Molecular epidemiology group, , van Gageldonk-Lafeber, A. B., Hahne, S. J. M., Reusken, C., Knol, M. J., Eggink, D.
10.1101/2021.11.24.21266735 — Posted: 2021-11-24 Discussion: Onsite
Modeling on Wastewater Treatment Process in Saudi Arabia: a perspective of Covid-19
Mutum, Z. M., Ahmadini, A. A., Hussein, A. M., Singh, Y. R.
10.1101/2021.11.22.21266599 — Posted: 2021-11-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).